top of page

Know Labs Enters into Research Agreement with Mayo Clinic

Updated: Sep 16, 2021

Seattle, WA. — July 21, 2020 — OTCQB: KNWN

Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced today that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor (CGM).

Phil Bosua, Know Labs CEO, stated, “We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBAND CGM.”

See About Know Labs, Inc. and our Safe Harbor Statement for company and regulatory information.


Recent Posts

See All

SEATTLE – August 14, 2023 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June

bottom of page